JP2016501223A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501223A5
JP2016501223A5 JP2015545193A JP2015545193A JP2016501223A5 JP 2016501223 A5 JP2016501223 A5 JP 2016501223A5 JP 2015545193 A JP2015545193 A JP 2015545193A JP 2015545193 A JP2015545193 A JP 2015545193A JP 2016501223 A5 JP2016501223 A5 JP 2016501223A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545193A
Other languages
English (en)
Japanese (ja)
Other versions
JP6382831B2 (ja
JP2016501223A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/072064 external-priority patent/WO2014085489A1/en
Publication of JP2016501223A publication Critical patent/JP2016501223A/ja
Publication of JP2016501223A5 publication Critical patent/JP2016501223A5/ja
Application granted granted Critical
Publication of JP6382831B2 publication Critical patent/JP6382831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545193A 2012-11-30 2013-11-26 アポトーシス阻害タンパク質(iap)のアンタゴニスト Active JP6382831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731794P 2012-11-30 2012-11-30
US61/731,794 2012-11-30
PCT/US2013/072064 WO2014085489A1 (en) 2012-11-30 2013-11-26 Inhibitor of apoptosis protein (iap) antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018101004A Division JP2018162256A (ja) 2012-11-30 2018-05-25 アポトーシス阻害タンパク質(iap)のアンタゴニスト

Publications (3)

Publication Number Publication Date
JP2016501223A JP2016501223A (ja) 2016-01-18
JP2016501223A5 true JP2016501223A5 (enExample) 2016-12-15
JP6382831B2 JP6382831B2 (ja) 2018-08-29

Family

ID=50828427

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015545193A Active JP6382831B2 (ja) 2012-11-30 2013-11-26 アポトーシス阻害タンパク質(iap)のアンタゴニスト
JP2018101004A Pending JP2018162256A (ja) 2012-11-30 2018-05-25 アポトーシス阻害タンパク質(iap)のアンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018101004A Pending JP2018162256A (ja) 2012-11-30 2018-05-25 アポトーシス阻害タンパク質(iap)のアンタゴニスト

Country Status (5)

Country Link
US (5) US9546174B2 (enExample)
EP (1) EP2925764B1 (enExample)
JP (2) JP6382831B2 (enExample)
CA (1) CA2896577C (enExample)
WO (1) WO2014085489A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085489A1 (en) 2012-11-30 2014-06-05 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック, インコーポレイテッド Protac抗体コンジュゲート及び使用方法
CA3121140A1 (en) * 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CN113573707A (zh) 2019-01-17 2021-10-29 德彪药业国际股份公司 用于治疗癌症的组合产品
CN110028508B (zh) * 2019-05-16 2021-05-28 南京华威医药科技集团有限公司 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂
CA3148504A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
EP4034102A1 (en) 2019-09-25 2022-08-03 Debiopharm International SA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
EP4058454A4 (en) * 2019-11-08 2023-12-13 Sanford Burnham Prebys Medical Discovery Institute APOPTOSIS INHIBITORS (IAP) PROTEIN ANTAGONISTS
US20230295181A1 (en) * 2020-04-30 2023-09-21 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
EP4426707A4 (en) * 2021-11-04 2025-10-22 Sanford Burnham Prebys Medical Discovery Inst APOPTOSIS INHIBITOR PROTEIN (IAP) ANTAGONISTS
AR131299A1 (es) * 2022-12-09 2025-03-05 Debiopharm Int Sa Nuevos inhibidores de iap, métodos para fabricarlos y usos de los mismos
WO2025090605A1 (en) * 2023-10-24 2025-05-01 University Of Houston System Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5457196A (en) 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5455242A (en) 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
AU673857B2 (en) 1992-10-30 1996-11-28 Aventisub Ii Inc. Mercaptoacetylamide bicyclic lactam derivatives
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
FR2803594B1 (fr) * 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
CN1960728A (zh) * 2004-01-16 2007-05-09 密歇根大学董事会 构象受限的smac模拟物及其应用
RS53734B1 (sr) 2004-07-02 2015-06-30 Genentech Inc. Inhibitori iap
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
US20100190688A1 (en) 2004-07-12 2010-07-29 Bin Chao Tetrapeptide analogs
WO2006133147A2 (en) * 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
US20090010941A1 (en) 2007-04-09 2009-01-08 University Of Massachusetts Methods for treating HIV
PT2139490E (pt) 2007-04-13 2014-10-08 Univ Michigan Miméticos bicíclicos diazo de smac e utilizações destes
CA2725398A1 (en) 2008-04-11 2009-10-15 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic smac mimetics and the uses thereof
JP2010174138A (ja) 2009-01-29 2010-08-12 Nok Kluber Kk グリース組成物の製造方法及び該方法により製造されるグリース組成物
US8642544B2 (en) * 2009-04-01 2014-02-04 Amylin Pharmaceuticals, Llc N-terminus conformationally constrained GLP-1 receptor agonist compounds
WO2012125622A1 (en) 2011-03-14 2012-09-20 Bristol-Myers Squibb Company Substituted adipic acid amides and uses thereof
CN104717974A (zh) 2012-06-06 2015-06-17 比奥诺尔免疫有限公司 疫苗
WO2014085489A1 (en) 2012-11-30 2014-06-05 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (iap) antagonists
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Hiv治療におけるアポトーシスタンパク質阻害剤(iap)のアンタゴニストの使用

Similar Documents

Publication Publication Date Title
JP2016501223A5 (enExample)
JP2009536620A5 (enExample)
JP2017509586A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
RU2016110096A (ru) Новое хинолин-замещенное соединение
JP2017522273A5 (enExample)
RU2011108281A (ru) Трипиридилкарбоксамидные антагонисты орексиновых рецепторов
RU2016150404A (ru) Пирроло[2,3-с]пиридины в качестве визуализирующих агентов для нейрофибриллярных клубков
RU2015141592A (ru) АРИЛ-СУЛЬФАМИДЫ И СУЛЬФАМАТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc
JP2014510727A5 (enExample)
RU2013123790A (ru) Ингибиторы cdk
JP2014511892A5 (enExample)
JP2013519684A5 (enExample)
JP2012522003A5 (enExample)
RU2016126503A (ru) Аналоги кортистатина, их синтез и применения
ME02558B (me) Inhibitori replikacije virusa gripa
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
AR076550A1 (es) Inhibidores de la janus tirosina kinasa (jak)
JP2013510120A5 (enExample)
JP2013056930A5 (enExample)
JP2014520767A5 (enExample)
JP2010511721A5 (enExample)
JP2016513130A5 (enExample)
JP2016503797A5 (enExample)